Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Breast Cancer Patients With Cancer Therapy-Related Cardiac Dysfunction
NCT05806138Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Vericiguat oral suspension (Formulation 4) in cancer therapy-related cardiac dysfunction (CTRCD), sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2023; status: active, not recruiting.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
cancer therapy-related cardiac dysfunction (CTRCD)
Beyond the preview
Go deeper on NCT05806138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806138.